The Center for Biosimilars® recaps the top news for the week of May 27, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 27.
Number 5: New bipartisan legislation has been introduced to promote biosimilar education.
Number 4: The Senate Committee on Health, Education, Labor, and Pensions released draft legislation aimed at lowering the cost of healthcare in the United States.
Number 3: A new Federal Trade Commission report found that fewer drug patent settlements include provisions that are likely to be anticompetitive.
Number 2: UnitedHealthcare announced that it will prefer the use of brand-name pegfilgrastim, Neulasta, over biosimilar options.
Number 1: Officials in British Columbia announced that many patients currently taking reference biologics will be switched to biosimilars within 6 months.
Finally, last week, our e-newsletter asked how important you think factors like on-body injection or reduced administration of growth factors are to biosimilar uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?